Business
Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Patent Trial and Appeal Board (\"PTAB\") of the United States Patent and Trademark Office (\"USPTO\") declared Interference No. 106,128 between Lipocine, Inc. (\"the Senior Party\") owned U.S. Patent Application and Clarus Therapeutics, Inc. (\"the Junior Party\") owned U.S. Patent Application. In preparation for the Interference, the USPTO withdrew the Clarus Application from issue.\n\n \n \n \n \n \n \n\n \nThis follows the pattern of previous Interferences as shown below:\nInterference No. 106,045 decided in Lipocine's favor and resulted in the cancellation of Clarus patent 8,828,428. Interference No. 106,120 decided in Lipocine's favor and resulted in the cancellation of Clarus application 15/723,976.\"We are pleased with the actions and judgements ordered by the PTAB which validates the strength of Lipocine's patent portfolio,\" said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine.\nAbout LipocineLipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product can...